학술논문
The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real‐life experience.
Document Type
Article
Author
the ITACOPS study group; Martini, Silvia; Carrai, Paola; Donato, Maria Francesca; Mazzarelli, Chiara; Rendina, Maria; Visco‐Comandini, Ubaldo; Filì, Daniela; Gianstefani, Alice; Caraceni, Paolo; Fagiuoli, Stefano; Melazzini, Mario; Montilla, Simona; Pani, Luca; Petraglia, Sandra; Russo, Pierluigi; Trotta, Maria Paola
Source
Subject
*LIVER transplantation
*HEPATITIS C diagnosis
*LIVER cancer patients
*HEPATITIS C treatment
*CIRRHOSIS of the liver
*LIVER cancer
*
*
*
*
*
Language
ISSN
1478-3223
Abstract
Abstract: Background & Aims: This study aimed to assess the real‐life clinical and virological outcomes of HCV waitlisted patients for liver transplantation (LT) who received sofosbuvir/ribavirin (SOF/R) within the Italian compassionate use program. Methods: Clinical and virological data were collected in 224 patients with decompensated cirrhosis and/or hepatocellular carcinoma (HCC) receiving daily SOF/R until LT or up a maximum of 48 weeks. Results: Of 100 transplanted patients, 51 were HCV‐RNA negative for >4 weeks before LT (SVR12: 88%) and 49 negative for <4 weeks or still viraemic at transplant: 34 patients continued treatment after LT (bridging therapy) (SVR12: 88%), while 15 stopped treatment (SVR12: 53%). 98 patients completed SOF/R without LT (SVR12: 73%). In patients with advanced decompensated cirrhosis (basal MELD ≥15 and/or C‐P ≥B8), a marked improvement of the scores occurred in about 50% of cases and almost 20% of decompensated patients without HCC reached a condition suitable for inactivation and delisting. Conclusions: These real‐life data indicate that in waitlisted patients: (i) bridging antiviral therapy can be an option for patients still viraemic or negative <4 weeks at LT; and (ii) clinical improvement to a condition suitable for delisting can occur even in patients with advanced decompensated cirrhosis. [ABSTRACT FROM AUTHOR]